BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer 2015;15:194. [PMID: 25884806 DOI: 10.1186/s12885-015-1203-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol 2019;12:38. [PMID: 30975222 DOI: 10.1186/s13045-019-0725-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
2 Greville-Heygate SL, Maishman T, Tapper WJ, Cutress RI, Copson E, Dunning AM, Haywood L, Jones LJ, Eccles DM. Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer. JCO Precis Oncol 2020;4:PO. [PMID: 32923877 DOI: 10.1200/PO.19.00178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ansari N, Shahrabi S, Khosravi A, Shirzad R, Rezaeean H. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer. Lab Med 2019;50:e36-41. [PMID: 31220302 DOI: 10.1093/labmed/lmz009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yin J, Yao M, Lu H, Cong X, Cui P, Liu Z. Primary uterine broad ligament ependymoma with CHEK2 p.H371Y germline mutation: A CARE-compliant case report uterine broad ligament ependymoma. J Obstet Gynaecol Res 2021. [PMID: 34716641 DOI: 10.1111/jog.15065] [Reference Citation Analysis]
5 Lang GT, Shi JX, Huang L, Cao AY, Zhang CH, Song CG, Zhuang ZG, Hu X, Huang W, Shao ZM. Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. Ann Transl Med 2020;8:1417. [PMID: 33313162 DOI: 10.21037/atm-20-2999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Apostolou P, Papasotiriou I. Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press) 2017;9:331-5. [PMID: 28553140 DOI: 10.2147/BCTT.S111394] [Cited by in Crossref: 16] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]